Drug
Certolizumab Pegol
Certolizumab Pegol: highest development phase Post-Market, developed by UCB. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Certolizumab pegol NCT01443364 | Post-Market | Rheumatoid Arthritis |
| CIMZIA | Approved | |
| Certolizumab Pegol (CZP) NCT01550003 | Phase 3 | Polyarticular-course Juvenile Idiopathic Arthritis (JIA) |
| Certolizumab Pegol NCT00175877 | Phase 3 | Rheumatoid Arthritis |
| Certolizumab pegol NCT01817972 | Phase 3 | Crohn's Disease |
| Certolizumab pegol NCT04740814 | Phase 1 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Certolizumab Pegol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.